Loading financials from SEC filings…
Health information services · Healthcare · Fiscal year ends Mar 31
Doximity reported revenue of $645M in the fiscal year ended Mar 2026, up 13.1% from the year before. Operating income was $215M, an operating margin of 33.3%, and net income was $196M. Operating cash flow of $326M less capital expenditure of $0 left free cash flow of $326M.
Ranks among the 4 health information services companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 344 | 419 | 475 | 570 | 645 |
| Cost of revenue | 39.8 | 53.5 | 50.7 | 55.9 | 70.3 |
| Gross profit | 304 | 366 | 425 | 515 | 575 |
| Research & development | 62.4 | 80.2 | 82.0 | 93.0 | 131 |
| Selling, general & admin | 128 | 160 | 171 | 191 | 229 |
| Operating income | 114 | 125 | 164 | 228 | 215 |
| Pre-tax income | 114 | 133 | 185 | 264 | 250 |
| Income tax | −40.8 | 20.3 | 37.6 | 40.4 | 54.0 |
| Net income | 155 | 113 | 148 | 223 | 196 |
| Diluted EPS | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| Diluted shares | 191 | 213 | 206 | 201 | 199 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 113 | 158 | 96.8 | 210 | 219 |
| Receivables | 81.1 | 107 | 101 | 128 | 145 |
| Current assets | 904 | 975 | 913 | 1,089 | 944 |
| Net PP&E | 8.5 | 11.3 | 12.3 | 13.7 | 18.1 |
| Goodwill | 18.9 | 67.9 | 67.9 | 67.9 | 85.0 |
| Total assets | 991 | 1,137 | 1,079 | 1,264 | 1,124 |
| Payables | 0.5 | 1.3 | 2.3 | 1.4 | 4.0 |
| Deferred revenue | 84.9 | 105 | 99.1 | 114 | 106 |
| Current liabilities | 111 | 140 | 147 | 156 | 155 |
| Total liabilities | 113 | 171 | 178 | 182 | 173 |
| Shareholders' equity | 879 | 966 | 901 | 1,083 | 951 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating cash flow | 127 | 180 | 184 | 273 | 326 |
| Capital expenditure | 1.9 | 1.7 | 0.1 | 0.0 | 0.0 |
| Free cash flow | 125 | 178 | 184 | 273 | 326 |
| Depreciation & amortisation | 5.0 | 10.3 | 10.3 | 10.7 | 14.4 |
| Stock-based compensation | 31.4 | 47.8 | 51.1 | 72.4 | 122 |
| Acquisitions | 0.0 | 53.5 | 0.0 | 0.0 | 26.5 |
| Share buybacks | 2.7 | 85.3 | 281 | 120 | 432 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 22.0% | 13.5% | 20.0% | 13.1% |
| Operating income growth (YoY) | – | 10.2% | 31.0% | 39.0% | −5.7% |
| EPS growth (YoY) | – | −24.3% | 35.8% | 54.2% | −11.7% |
| Gross margin | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Operating margin | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Net margin | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| Return on equityBlank when equity is negative | 17.6% | 11.7% | 16.4% | 20.6% | 20.6% |
| ROCEEBIT ÷ (assets − current liabilities) | 12.9% | 12.5% | 17.6% | 20.6% | 22.2% |
| Free cash flow margin | 36.3% | 42.5% | 38.7% | 47.9% | 50.6% |
| Cash conversion (CFO ÷ net income) | 0.82x | 1.59x | 1.25x | 1.22x | 1.67x |
| Receivable days | 86 | 93 | 78 | 82 | 82 |
| Payable days | 4 | 9 | 16 | 9 | 21 |
| Current ratio | 8.12x | 6.99x | 6.20x | 6.97x | 6.09x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.